The Multiple Myeloma Channel on VJHemOnc is an independent medical education platform, supported with funding from BMS (Gold) and Legend Biotech (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
ASCO 2017 | SWOG S0777 trial: lenalidomide, dexamethasone and bortezomib for the treatment of MM
Maria-Victoria Mateos, MD, PhD, from the University Hospital of Salamenca, Salamenca, Spain, provides us an overview of the SWOG S0777 trial, a Phase III study evaluating the effectiveness of lenalidomide and dexamethasone with or without bortezomib in treating patients with previously untreated multiple myeloma (MM) (NCT00644228). Here, she also evaluates the role of minimal residual disease (MRD) as a marker for predicting the PFS and OS of MM patients. This interview was filmed at the American Society of Oncology (ASCO) 2017 Annual Meeting in Chicago, IL.
